Navigation Links
Medpace Strengthens Presence in Central Europe
Date:8/21/2007

CINCINNATI and PRAGUE, Czech Republic, Aug. 21 /PRNewswire/ -- Medpace, Inc., a leading global full-service contract research organization, today announced it has completed the acquisition of Monax s.r.o., a regional contract research organization (CRO) headquartered in Prague, Czech Republic. This move strengthens the Medpace presence in Central Europe and expands its capacity to provide full service clinical research management within the Czech Republic and Slovakia. Petr Potuznik, MD, the founder of Monax, will continue to lead Medpace clinical operations for the region.

"We are excited to welcome the Monax team to the Medpace family," said August Troendle, MD, Medpace Chief Executive Officer. "The expertise of Dr. Petr Potuznik and his highly trained team fit perfectly within our strategic global expansion plan."

"We have worked closely with Medpace in the past and found that our companies shared a high level of expertise and commitment to quality," said Potuznik. "Becoming part of the Medpace group allows the Monax team to grow and expand our presence and capabilities throughout the region."

About Medpace

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development - from program planning and execution to product approval.

With more than 500 employees and clinical trial experience in nearly 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

The Medpace group of companies also includes

Imagepace - a centralized imaging laboratory with expertise in cIMT

Medpace Reference Laboratory - a centralized lab with therapeutically specialized testing

Medpace Clinical Pharmacology - a Phase I/IIa unit scheduled to open in Q1, 2008.

Contact: Stephanie Lusk 513-579-9911 x1102


'/>"/>
SOURCE Medpace, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BIO 2007: Wisconsin makes its presence felt
2. TDS trades markets to gain Duluth presence
3. West Coast VC Establishes Midwest Presence in Madison
4. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
5. Madison start-up Central Signal gets $350K grant
6. Will wireless Internet bypass the central city?
7. Norlight to expand fiber network into central Illinois
8. Centralization mania takes over
9. Meterologix Media Division acquired by Madison-based Weather Central
10. Weather Central launches second satellite
11. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):